Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 6 / 2025
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Copenhagen, Denmark, March 25, 2025 – Zealand Pharma A/S ('Zealand') (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 24 March 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:
As of 24 March 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,106,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.00% of the total share capital and 10.05% of the total voting rights in Zealand Pharma A/S.
Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V. (Dutch registration no. 75092395), which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543). Ultimately, Van Herk Private Equity Investments B.V. is owned and controlled by Mr. Adrianus van Herk.
Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,106,191 shares (each share carrying one vote), corresponding to 10.00% of the total share capital and 10.05% of the total voting rights in Zealand Pharma A/S.
Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.
Please see further details in the attached notification form.
# # #
About Zealand Pharma Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed products.
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a team in the U.S. For more information about Zealand Pharma's business and activities, please visit www.zealandpharma.com.
ContactAnna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate CommunicationsZealand PharmaEmail: akrassowska@zealandpharma.com
Adam Lange (Investors)Investor Relations OfficerZealand PharmaEmail: alange@zealandpharma.com
Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@zealandpharma.com
Attachments
20250324 FSA - Standardformular english Van Herk Investments BV_signed
20250324 FSA - Standardformular english Van Herk Management Services BV_signed
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
The AI Trade Is Back in Play: 2 Stocks to Buy for Summer Sizzle!
Written by Joey Frenette at The Motley Fool Canada The AI (artificial intelligence) trade is getting heated as we move towards the midpoint of the year, with the S&P 500 now just a good day or two away from completing its so-called V-shaped recovery from the brutal spring correction (nearly a bear market for the S&P 500 as the TSX Index held its own relatively well) worsened by Trump's sweeping tariff war with most of the world. If you're a tad jittery after the volatility experienced a few months ago, you're not alone. It's hard to justify buying the stock on strength as tariff talks continue to dominate the headlines. In any case, I think there are great value names that don't entail paying all too high a premium for long-term AI exposure. In this piece, we'll have a look at two great names for investors seeking growth at a reasonable price (GARP). As GARP clashes with the AI trade, I think the following names could be timely bets for the medium and long term. Apple (NASDAQ:AAPL) stock seems stuck in a bear market, with shares falling below the $200 level again following what can only be described as a less-than-exciting 2025 edition of WWDC (Worldwide Developers' Conference). I saw the whole thing, and it was lighter in the AI than expected. After facing criticism for overpromising with its Apple Intelligence, which may be an early flop depending on who you ask, I think it's no surprise that the latest WWDC was a bit lighter on the AI promises. Does that mean Apple is ready to step away from the AI race? Of course not! Rather, I think Apple's just underpromising so that it can overdeliver a year or two from now. Indeed, there's a high bar to pass for the next-level Siri to land. And it's not yet above the high bar set by Apple. Despite the less-exciting and relatively AI-light WWDC, I still consider Apple to be a top AI play that'll be worth the wait. For now, there's Liquid Glass technology to get excited about as Apple applies more polish to its model that it wants to get right, even if it means showing up even later to the AI party. After slipping more than 23% from its highs over AI jitters and underwhelming post-WWDC, I think it's time to start thinking about doing some buying. Indeed, the stock is down nearly 7% in the past year, with a forward price-to-earnings multiple of 25.1 times, which is way too low for a firm that's going slow and steady in this AI race. I think slow and steady may very well win the race. But, of course, time will tell. I've been pounding the table on Shopify (TSX:SHOP) and its AI potential for quite some time now (likely well over a year). And recently, I highlighted that some analysts covering the stock are starting to take notice. Indeed, Wall Street is catching on to the company's AI prowess. And with that, I believe, could accompany multiple expansion as the firm continues investing heavily in AI technologies to level up its product. Personally, I think Shopify is the most innovative tech firm in Canada and perhaps in the e-commerce scene. As such, investors may wish to watch the name to buy on any dips over the coming weeks and months. Shopify is the real deal. And to discount its AI powers, I think, would be a mistake. The post The AI Trade Is Back in Play: 2 Stocks to Buy for Summer Sizzle! appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Joey Frenette has positions in Apple. The Motley Fool has positions in and recommends Shopify. The Motley Fool recommends Apple. The Motley Fool has a disclosure policy. 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Oak Park Heights announces new mayor, available council seat
The city of Oak Park Heights announced Wednesday that Chuck Dougherty will be taking over the position of Oak Park Heights mayor after the death of Mayor Mary McComber in May. McComber served as mayor from 2012 to 2025. 'Mayor McComber left some big shoes to fill, but in this time of transition, I am committed to providing steady leadership and ensuring continuity for our community,' Dougherty said in the announcement. 'I look forward to continuing to serve our community with dedication, working alongside our Council, staff and residents.' Dougherty previously served as deputy mayor and has had a seat on the Oak Park Heights City Council since 2013. He and his wife also own the Water Street Inn and the Cover Park Manor Bed & Breakfast. The city council is accepting applications for Dougherty's vacated council seat through Thursday, July 3, according to the announcement. Dougherty and the new council member will serve in these roles until November 2026, when a special election for the positions will occur. Both special elections would be for a two-year term to finish the remaining terms of McComber and Dougherty. Applications for Oak Park Heights City Council can be found on the city's website at or at City Hall at 14168 Oak Park Blvd. N. As mayor, Dougherty will help plan for the 2028 closure of the Allen S. King plant in Oak Park Heights. The plant currently provides close to 28 percent of Oak Park Heights' tax base. When running for city council in 2024, Dougherty said one of his priorities was coming up with a plan to minimize the effects the tax base loss will have on Oak Park Heights residents. Obituary: How a bridge got Mary McComber, mayor of Oak Park Heights, into local politics U of M researchers are planting 'survivor' trees in hopes of defeating Dutch elm disease State fund helps Oak Park Heights plan for PFAS treatment Oak Park Heights state of emergency declared to deal with water main break Four Stillwater teachers suspended for cheating on training program
Yahoo
an hour ago
- Yahoo
Why Oklo Stock Slumped Today
The company priced its upcoming secondary share issue. It's selling its common stock at $60 apiece. 10 stocks we like better than Oklo › One of the hotter energy stocks of recent times cooled down on Friday. This is next-generation nuclear company Oklo (NYSE: OKLO), which provided details of a capital-raising effort it originally announced late Wednesday afternoon. Investors weren't all that happy with this, and on Friday, they traded the stock down to leave it with a more than 1% loss in value. After market hours Thursday, Oklo provided more information about the secondary share issue it disclosed the previous day. The issue has been priced at $60 per share, more than $4 below Thursday's closing price. The company is to float nearly 6.7 million shares of its class A common stock, so the issue is set to raise gross proceeds of slightly over $400 million. The issue's underwriting syndicate is led by Goldman Sachs and Bank of America Securities and includes Citigroup, JPMorgan Chase's J.P. Morgan, and UBS Investment Bank. The underwriters have been granted a 30-day option to collectively purchase up to 1 million additional shares at that $60 per share price. The offering should close this coming Monday, June 16. Despite recent successes, such as its receipt of a notice of intent to award (NOITA) a project on an Alaska base for the Air Force, Oklo is still at a relatively early stage as a company. As such, it continues to be hungry for capital to sustain its operations. The downside of this, of course, is the dilutive nature of share issues. This one isn't particularly so, as Oklo has more than 139 million shares currently outstanding. Still, it's surely spooking investors who worry that there are more, and larger, share issues to come. Before you buy stock in Oklo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Oklo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Bank of America is an advertising partner of Motley Fool Money. Citigroup is an advertising partner of Motley Fool Money. JPMorgan Chase is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bank of America, Goldman Sachs Group, and JPMorgan Chase. The Motley Fool has a disclosure policy. Why Oklo Stock Slumped Today was originally published by The Motley Fool Sign in to access your portfolio
